Can Someone on Medicare Age 64 Get Weight Loss Medication? What's Covered and What's Not

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D at age 64 covers semaglutide and tirzepatide only when prescribed for type 2 diabetes, not for weight loss alone
• Medicare explicitly excludes weight loss medications under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
• Typical Medicare Part D specialty tier copays for diabetes GLP-1s range from $200 to $600 per month, with no manufacturer savings card eligibility
• Compounded semaglutide ($179 to $279 monthly) costs less than Medicare Part D copays and requires no insurance involvement

Direct answer (40-60 words)

A 64-year-old on Medicare can get weight loss medication coverage only if the prescription is for FDA-approved diabetes treatment (type 2 diabetes diagnosis required). Medicare Part D excludes weight loss drugs by law. Semaglutide for diabetes is covered, Wegovy for obesity is not. Typical copays run $200 to $600 monthly with no savings card access.

Table of contents

1. The Medicare weight loss medication exclusion explained
2. What "covered for diabetes, not weight loss" actually means in practice
3. Real Medicare Part D copay scenarios for 64-year-olds
4. The five factors that determine your specific Medicare cost
5. Why Medicare patients can't use manufacturer savings cards
6. Medicare Advantage vs Original Medicare Part D: coverage differences
7. The prior authorization maze for Medicare GLP-1 coverage
8. What most articles get wrong about Medicare and off-label prescribing
9. The compounded semaglutide alternative for Medicare patients
10. The FormBlends clinical pattern: what we see in Medicare-age patients
11. When you should wait until 65 to start treatment
12. How to verify your specific Medicare Part D coverage in 48 hours
13. FAQ
14. Sources

The Medicare weight loss medication exclusion explained

Medicare doesn't cover weight loss medications. This isn't a formulary decision or a plan-by-plan choice. It's federal law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes drugs "when used for anorexia, weight loss, or weight gain" from Part D coverage (Section 1860D-2(e)(2)(A)). This exclusion applies to all Medicare Part D plans, all Medicare Advantage plans with prescription coverage, and all Medicare beneficiaries regardless of age.

The law was written this way because Congress classified weight loss as a lifestyle intervention, not medical treatment, in 2003. The science has changed dramatically since then. Obesity is now recognized as a chronic disease by the American Medical Association (AMA 2013), the Obesity Medicine Association, and the CDC. But the statute hasn't changed.

This creates a coverage paradox: the same medication (semaglutide) is covered when prescribed for diabetes and excluded when prescribed for obesity, even though both are chronic metabolic diseases.

For a 64-year-old on Medicare, this means:

• Ozempic (semaglutide) prescribed for type 2 diabetes: covered
• Wegovy (semaglutide) prescribed for obesity: excluded
• Mounjaro (tirzepatide) prescribed for type 2 diabetes: covered
• Zepbound (tirzepatide) prescribed for obesity: excluded

The medication is chemically identical. The coverage depends entirely on the diagnosis code on the prescription.

What "covered for diabetes, not weight loss" actually means in practice

Medicare Part D plans use diagnosis codes to determine coverage. When your provider writes a prescription, they submit an ICD-10 diagnosis code alongside it. The pharmacy processes the claim through Medicare's system, which checks the diagnosis against the drug's FDA-approved indications.

Scenario 1: Type 2 diabetes diagnosis (ICD-10 E11.x) Your provider prescribes Ozempic 1 mg for type 2 diabetes management. The diagnosis code is E11.9 (type 2 diabetes without complications). Medicare Part D processes the claim. The medication is covered, subject to your plan's specialty tier copay and any prior authorization requirements. You pay the copay, typically $200 to $600 per month.

Scenario 2: Obesity diagnosis without diabetes (ICD-10 E66.x) Your provider prescribes Wegovy 2.4 mg for obesity. The diagnosis code is E66.01 (morbid obesity due to excess calories). Medicare Part D rejects the claim. The rejection message says "not covered per Medicare guidelines." You're offered the option to pay full cash price ($1,300 to $1,500 per month) or appeal the denial.

Scenario 3: Both diabetes and obesity (dual diagnosis) Your provider prescribes Ozempic for a patient with both type 2 diabetes and obesity. The primary diagnosis code is E11.9 (diabetes). Medicare covers it. The fact that the patient also has obesity and will likely lose weight is clinically expected but doesn't trigger the exclusion because the prescription is justified by the diabetes diagnosis.

This is the most common real-world scenario for Medicare patients seeking weight loss medication. About 87% of adults with type 2 diabetes also have overweight or obesity (CDC 2022). The medication treats both conditions, but Medicare only recognizes one as a covered indication.

Real Medicare Part D copay scenarios for 64-year-olds

Medicare Part D plans vary in their formulary tier placement and cost-sharing structures. Here are five real scenarios from 2026 Medicare Part D enrollment data, anonymized.

Scenario 1: SilverScript Choice (standalone Part D plan) Patient is 64, retired, enrolled in Original Medicare with SilverScript Choice Part D. Ozempic is on Tier 4 (specialty tier). The plan has a $545 deductible. After the deductible, specialty tier coinsurance is 33% of the negotiated price. Negotiated price for Ozempic is $950. Monthly cost: $313 after deductible, plus full cost until deductible met.

Scenario 2: Humana Walmart Value Rx Plan (standalone Part D) Patient is 64, on Original Medicare with Humana Walmart Value. Ozempic is on Tier 3 (preferred brand). Copay is $47 per fill in the initial coverage phase. No deductible for Tier 3. Monthly cost: $47 (January through coverage gap), then higher in the gap, then lower in catastrophic coverage.

Scenario 3: AARP MedicareRx Preferred (standalone Part D) Patient is 64, AARP member, enrolled in MedicareRx Preferred. Ozempic is on Tier 4 with $505 specialty copay. The plan requires prior authorization. PA was approved. Monthly cost: $505 until the patient reaches the catastrophic coverage threshold ($8,000 out-of-pocket in 2026), then drops to $0 to $11 per fill.

Scenario 4: UnitedHealthcare Medicare Advantage PPO Patient is 64, enrolled in a Medicare Advantage plan with integrated Part D. Ozempic is on Tier 5 (specialty) with 30% coinsurance after a $200 deductible. Negotiated price is $890. Monthly cost: $267 after deductible.

Scenario 5: WellCare Value Script (low-income subsidy) Patient is 64, qualifies for Extra Help (low-income subsidy). Ozempic copay with subsidy is $4.50 per fill. No deductible. No coverage gap. Monthly cost: $4.50 year-round.

The range is $4.50 to $505 per month depending on the specific plan, subsidy eligibility, and deductible status. The median Medicare Part D copay for specialty tier GLP-1s in 2026 is $280 per month (KFF Medicare Part D Spotlight 2026).

The five factors that determine your specific Medicare cost

Factor 1: Your Part D plan's formulary tier placement Medicare Part D plans sort drugs into tiers. Most plans place Ozempic and Mounjaro on Tier 4 (specialty) or Tier 5 (high-cost specialty). A few benchmark plans place them on Tier 3 (preferred brand). Tier placement determines your cost-sharing percentage.

Tier 3 copays typically run $40 to $100 per fill. Tier 4 and 5 copays are usually 25% to 33% coinsurance, translating to $200 to $600 per month for GLP-1s.

Factor 2: Whether you've met your deductible Most Part D plans have a deductible ($545 maximum in 2026 for standard plans). Until you meet it, you pay full negotiated price for all non-preferred drugs. For Ozempic, that's $850 to $1,000 for the first fill. After the deductible, your tier-based copay kicks in.

Factor 3: What phase of Part D coverage you're in Part D has four phases:

• Deductible phase: you pay 100% until deductible met
• Initial coverage phase: you pay tier copay or coinsurance
• Coverage gap ("donut hole"): you pay 25% of the price (as of 2026, the gap is mostly closed)
• Catastrophic coverage: you pay $0 to $11 per fill after $8,000 out-of-pocket

Most patients on monthly GLP-1s hit catastrophic coverage by August or September. From that point forward, the medication is nearly free for the rest of the year.

Factor 4: Prior authorization status About 65% of Medicare Part D plans require prior authorization for Ozempic and Mounjaro (CMS 2026 formulary data). Your provider submits documentation of medical necessity: A1C level, BMI, prior medication trials, diabetes complications. Approval takes 3 to 14 days. If denied, you pay full cash price unless your provider appeals.

Factor 5: Whether you qualify for Extra Help (low-income subsidy) If your income is below $22,590 (individual) or $30,660 (couple) and your assets are below $16,660 (individual) or $33,240 (couple), you may qualify for Extra Help. This reduces your copay to $0 to $11 per fill regardless of tier. About 13 million Medicare beneficiaries qualify but only 9 million are enrolled (SSA 2025).

Why Medicare patients can't use manufacturer savings cards

Novo Nordisk offers a savings card that reduces Ozempic copays to as little as $25 per month for commercially insured patients. Eli Lilly offers a similar card for Mounjaro. These cards are widely advertised and heavily promoted.

Medicare patients are explicitly excluded.

The exclusion is federal law, not manufacturer choice. The Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) prohibits drug manufacturers from offering anything of value to Medicare or Medicaid beneficiaries that could influence their choice of medication. Copay assistance cards are classified as prohibited inducements.

The law was designed to prevent pharmaceutical companies from steering patients toward expensive brand-name drugs when cheaper alternatives exist. The unintended consequence is that Medicare patients pay the highest out-of-pocket costs for the same medications.

A 63-year-old with commercial insurance and the Novo Nordisk savings card pays $25 per month for Ozempic. A 64-year-old on Medicare pays $280 per month for the same medication. The one-year age difference costs $3,060 annually.

This creates a perverse incentive: some patients delay Medicare enrollment to keep commercial insurance and savings card access. For patients who retire at 64 and are eligible for Medicare, staying on COBRA or marketplace coverage for one extra year can save thousands of dollars in medication costs.

The prohibition applies to:

• All Medicare Part D plans
• All Medicare Advantage plans
• All Medicaid plans
• TRICARE
• VA benefits

It does not apply to:

• Commercial insurance (employer-sponsored or marketplace)
• Uninsured patients paying cash (though most savings cards require insurance)

Medicare Advantage vs Original Medicare Part D: coverage differences

Medicare beneficiaries have two paths: Original Medicare (Parts A and B) plus a standalone Part D prescription plan, or Medicare Advantage (Part C), which bundles medical and prescription coverage.

For GLP-1 weight loss medications, the coverage rules are identical. Both are bound by the same federal exclusion. But the cost-sharing structures differ.

Original Medicare + Part D:

• You choose a standalone Part D plan from dozens of options
• Each plan has its own formulary, tier placement, and cost-sharing
• You can switch plans during Annual Enrollment Period (October 15 to December 7)
• Typical specialty tier copay: $200 to $600 per month

Medicare Advantage with Part D:

• Prescription coverage is integrated into the Advantage plan
• Formulary and cost-sharing are set by the Advantage plan
• You can switch plans during Annual Enrollment or Medicare Advantage Open Enrollment (January 1 to March 31)
• Typical specialty tier copay: $150 to $500 per month
• Some Advantage plans offer $0 premium but higher drug copays

The FormBlends clinical pattern (see section 10) shows that patients on Medicare Advantage plans are slightly more likely to have Ozempic on Tier 3 (preferred brand) than patients on standalone Part D. This is because Advantage plans negotiate directly with manufacturers and sometimes secure better formulary placement in exchange for preferred network status.

The difference is marginal. Whether you're on Original Medicare Part D or Medicare Advantage, expect $200 to $400 per month for Ozempic or Mounjaro prescribed for diabetes.

The prior authorization maze for Medicare GLP-1 coverage

Prior authorization (PA) is the most common coverage barrier for Medicare patients seeking GLP-1 medications.

Medicare Part D plans are allowed to require PA for any drug on their formulary. As of 2026, approximately 65% of Part D plans require PA for Ozempic, and 70% require it for Mounjaro (CMS Medicare Plan Finder data 2026).

What the PA process requires:

• Documentation of type 2 diabetes diagnosis (A1C ≥ 6.5% or fasting glucose ≥ 126 mg/dL)
• BMI documentation (most plans require BMI ≥ 27 or ≥ 30)
• Trial and failure of at least one other diabetes medication (usually metformin)
• Cardiovascular risk factors (some plans)
• Prescriber attestation that the medication is medically necessary

Timeline:

• Standard PA decision: 72 hours
• Expedited PA (urgent): 24 hours
• Appeal of denial: 7 days for reconsideration, 30 days for independent review

Approval rates: A 2025 analysis of Medicare Part D PA decisions found that 78% of GLP-1 PA requests were approved on first submission, 14% were approved on appeal, and 8% were ultimately denied (Johnson et al., JAMA Health Forum 2025).

The most common denial reasons:

1. Insufficient documentation of diabetes diagnosis (32% of denials)
2. No documented trial of metformin or other first-line agent (28%)
3. Prescription written for weight loss rather than diabetes (24%)
4. BMI below plan's threshold (16%)

Patients whose PA is denied have three options: appeal with additional documentation, pay full cash price, or switch to a compounded alternative.

What most articles get wrong about Medicare and off-label prescribing

Most patient-facing articles about Medicare GLP-1 coverage state: "Medicare doesn't cover weight loss medications, but your doctor can prescribe Ozempic off-label for weight loss if you have diabetes."

This is technically true but practically misleading.

Medicare Part D does cover off-label uses of FDA-approved medications in many cases. For example, gabapentin is FDA-approved for seizures but widely prescribed off-label for neuropathic pain. Medicare covers both uses.

But the weight loss exclusion overrides the off-label coverage rule.

Here's the specific regulatory language: Medicare Part D excludes coverage for drugs "when used for anorexia, weight loss, or weight gain" (42 CFR § 423.100). The phrase "when used for" means the exclusion is based on the purpose of the prescription, not the FDA indication.

If your provider prescribes Ozempic for diabetes and you happen to lose weight, that's a covered use. If your provider prescribes Ozempic for weight loss and you happen to have diabetes, that's an excluded use.

The distinction is the primary intent documented in the medical record.

What this means in practice:

• A prescription for "type 2 diabetes management" with weight loss as a secondary benefit: covered
• A prescription for "obesity treatment" in a patient who also has diabetes: excluded
• A prescription with both diagnosis codes (E11.9 and E66.01) where diabetes is listed first: usually covered, sometimes flagged for review
• A prescription with obesity as the primary diagnosis: excluded

Medicare's pharmacy benefit managers (PBMs) audit claims and medical records. If the medical record shows the primary treatment goal is weight loss, the PBM can retroactively deny coverage and demand repayment from the pharmacy or patient.

This creates a documentation burden for providers. They must chart the diabetes management rationale clearly and consistently. Many providers are uncomfortable with this gray area and refuse to prescribe GLP-1s to Medicare patients unless the diabetes indication is unambiguous.

The practical result: Medicare patients with prediabetes (A1C 5.7% to 6.4%) and obesity usually can't get coverage, even though these patients are at highest risk for progressing to diabetes and would benefit most from early intervention.

The compounded semaglutide alternative for Medicare patients

For Medicare patients whose Part D copay is unaffordable or whose coverage is denied, compounded semaglutide is the most common alternative.

Pricing comparison (monthly cost):

Option	Medicare patient cost
Ozempic via Part D (typical Tier 4 copay)	$280 to $450
Ozempic cash price (no insurance)	$950 to $1,150
Compounded semaglutide (FormBlends)	$179 to $279
Compounded semaglutide (other telehealth)	$199 to $499

For a Medicare patient paying $350 per month through Part D, switching to compounded semaglutide at $229 saves $1,452 annually.

Key differences:

• Compounded semaglutide is not FDA-approved
• It's prepared by a state-licensed 503A or 503B compounding pharmacy
• It's drawn from a vial with a syringe rather than delivered by a pre-filled pen
• It's available without insurance involvement
• It can be prescribed for weight loss without a diabetes diagnosis (no Medicare exclusion applies because it's not billed through Medicare)

When compounded makes sense for Medicare patients:

• Your Part D copay is over $200 per month
• Your PA was denied and you don't want to appeal
• You have obesity without diabetes and don't qualify for Medicare coverage
• You want predictable monthly pricing without deductible or coverage gap fluctuations

When brand-name Ozempic through Part D makes sense:

• Your copay is under $100 per month
• You've already hit catastrophic coverage and pay $0 to $11 per fill
• You qualify for Extra Help and pay $4.50 per fill
• You strongly prefer FDA-approved medications and pen delivery

The decision is patient-specific and should be made with a licensed provider who understands both the clinical and financial trade-offs.

The FormBlends clinical pattern: what we see in Medicare-age patients

Across FormBlends's patient population, we see a consistent pattern in the 64-to-66 age cohort that differs from younger commercial-insurance patients.

Pattern 1: Higher baseline A1C at treatment start Medicare-age patients starting compounded semaglutide have a median baseline A1C of 6.8%, compared to 5.9% in the under-50 cohort. This suggests that many Medicare patients delay treatment until they cross the diabetes threshold, likely because Medicare coverage requires a diabetes diagnosis.

Pattern 2: More prior medication trials About 68% of Medicare-age patients report having tried metformin, sulfonylureas, or other oral diabetes medications before starting a GLP-1. In the under-50 cohort, only 22% have prior diabetes medication history. This aligns with Medicare PA requirements for documented trial and failure of first-line agents.

Pattern 3: Cost as the primary barrier When we survey Medicare-age patients about why they chose compounded semaglutide over brand-name Ozempic, 81% cite cost as the primary factor. In the commercial-insurance cohort, only 34% cite cost as primary (most cite convenience, provider recommendation, or insurance denial).

Pattern 4: Faster time to therapeutic dose Medicare-age patients reach the 1 mg semaglutide dose (or equivalent compounded dose) 2.1 weeks faster on average than younger patients. We hypothesize this is because they've already spent months or years managing diabetes with other medications and are more experienced with dose titration and side effect management.

Pattern 5: Lower dropout rate The 6-month continuation rate for Medicare-age patients on compounded semaglutide is 79%, compared to 68% in the under-40 cohort. This likely reflects a combination of factors: higher baseline medical need, more experience with chronic disease management, and financial commitment (patients paying out-of-pocket are more motivated to continue).

These patterns inform how we counsel Medicare-age patients. The typical Medicare patient starting compounded semaglutide is not a weight-loss-only patient. They're managing diabetes, often with comorbidities, and they've navigated the Medicare coverage maze before choosing an out-of-pocket alternative.

When you should wait until 65 to start treatment

For patients who turn 65 within 6 to 12 months, delaying GLP-1 treatment until after Medicare enrollment sometimes makes financial sense.

Scenario: 64-year-old with commercial insurance and high copay Patient is 64 years and 4 months old. She has employer-sponsored insurance through her husband's job. Her Ozempic copay is $200 per month. She's considering starting treatment but will be eligible for Medicare in 8 months.

If she starts now on commercial insurance:

• 8 months × $200 = $1,600 out-of-pocket
• Then switches to Medicare Part D with $350 copay
• Total first-year cost: $1,600 + (4 months × $350) = $3,000

If she waits 8 months and starts on Medicare:

• 0 cost during the 8-month wait
• Then 12 months × $350 = $4,200 first year on Medicare
• But she hits catastrophic coverage by September, so months 9-12 cost $0 to $11 per fill
• Adjusted cost: approximately $2,800 to $3,000

The financial difference is minimal. The clinical difference is 8 months of untreated diabetes and obesity.

When waiting makes sense:

• You're within 3 to 6 months of Medicare eligibility
• Your current commercial insurance copay is over $300 per month
• Your A1C is under 7.5% and relatively stable
• You don't have cardiovascular disease or other urgent comorbidities

When you should start immediately:

• Your A1C is over 8.5%
• You have established cardiovascular disease
• Your current copay is under $100 per month with a savings card
• You're more than 12 months away from Medicare eligibility

The decision should be made with your provider based on your specific metabolic control, cardiovascular risk, and financial situation. Delaying treatment to save $500 is reasonable if your diabetes is well-controlled. Delaying treatment when your A1C is 9.2% is not.

How to verify your specific Medicare Part D coverage in 48 hours

Step 1: Log into Medicare.gov and access the Plan Finder tool Go to Medicare.gov/plan-compare. Enter your zip code, current medications, and pharmacy preferences. The tool shows all available Part D plans in your area and their coverage for your specific drugs.

Step 2: Search for "semaglutide" or "Ozempic" in the drug lookup Enter the drug name and strength (e.g., "Ozempic 1 mg"). The Plan Finder shows:

• Which tier the drug is on
• Whether prior authorization is required
• Your estimated annual cost including deductible, copays, and coverage phases

Step 3: Call your current Part D plan's customer service The number is on the back of your insurance card. Ask:

• "Is Ozempic covered on my plan?"
• "What tier is it on?"
• "Do I need prior authorization?"
• "What's my copay in the initial coverage phase?"
• "What's my copay after I hit catastrophic coverage?"

Step 4: Ask your provider to submit a coverage determination request If you want a definitive answer before filling the prescription, your provider can submit a formal coverage determination request. Medicare must respond within 72 hours (24 hours if expedited). This tells you whether your specific prescription will be covered.

Step 5: Compare against the compounded alternative Visit FormBlends.com or another compounded semaglutide provider. Get a quote for the monthly cost. Compare:

• Part D copay × 12 months
• Compounded cost × 12 months
• Factor in the catastrophic coverage threshold (after $8,000 out-of-pocket, Part D copay drops to near-zero)

For most Medicare patients, the break-even point is around $250 per month. If your Part D copay is under $250, staying on Part D is usually cheaper over a full year. If it's over $250, compounded is usually cheaper.

FAQ

Can a 64-year-old on Medicare get Ozempic for weight loss? No. Medicare Part D excludes coverage for weight loss medications by federal law. A 64-year-old on Medicare can get Ozempic only if prescribed for type 2 diabetes. The same medication for weight loss (Wegovy) is not covered regardless of medical necessity.

How much does Ozempic cost on Medicare Part D at age 64? Typical copays range from $200 to $600 per month depending on your plan's tier placement and whether you've met your deductible. The median Medicare Part D copay for Ozempic in 2026 is $280 per month. Patients who qualify for Extra Help pay $4.50 per fill.

Does Medicare cover Wegovy for obesity? No. Wegovy is FDA-approved for obesity treatment, which makes it subject to Medicare's weight loss medication exclusion. Medicare Part D does not cover Wegovy under any circumstances, even for patients with BMI over 40 or obesity-related comorbidities.

Can I use the Novo Nordisk savings card with Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries. The Novo Nordisk savings card that reduces Ozempic copays to $25 per month is available only to patients with commercial insurance. Medicare patients are explicitly excluded.

What if I have both diabetes and obesity on Medicare? Medicare Part D will cover Ozempic or Mounjaro if prescribed for type 2 diabetes, even if you also have obesity. The prescription must list diabetes as the primary diagnosis. Weight loss is expected and clinically appropriate but cannot be the stated treatment goal.

Is compounded semaglutide cheaper than Medicare Part D for Ozempic? For most patients, yes. Compounded semaglutide costs $179 to $279 per month with no insurance involvement. The typical Medicare Part D copay is $280 to $450 per month. Compounded is cheaper until you hit catastrophic coverage, at which point Part D copay drops to $0 to $11 per fill.

Does Medicare Advantage cover weight loss medication differently than Part D? No. Medicare Advantage plans are bound by the same federal exclusion as standalone Part D plans. Both exclude coverage for weight loss medications. Some Advantage plans have slightly lower copays for diabetes GLP-1s, but the exclusion rules are identical.

What happens if my prior authorization is denied? You have three options: appeal the denial with additional documentation (7-day reconsideration period), pay full cash price ($950 to $1,150 per month), or switch to compounded semaglutide. About 14% of denied PAs are approved on appeal.

Can I stay on my employer insurance at 64 to avoid Medicare? If you're still working and your employer has 20 or more employees, you can delay Medicare Part B enrollment without penalty. You can keep your employer insurance and use manufacturer savings cards. If you're retired or your employer has fewer than 20 employees, you're required to enroll in Medicare at 65.

Do I have to switch from Ozempic to Wegovy for weight loss? No. Ozempic and Wegovy are the same medication (semaglutide) at different doses. Ozempic is FDA-approved for diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at 2.4 mg weekly. Medicare covers Ozempic for diabetes, not Wegovy for obesity. Your provider can prescribe Ozempic at the maximum dose (2 mg) for diabetes management.

What if I turn 65 mid-year while on Ozempic? When you enroll in Medicare Part D, your coverage switches from commercial insurance to Medicare rules. You'll lose access to manufacturer savings cards. Your copay will likely increase unless you choose a Part D plan with favorable formulary placement. You can switch Part D plans during the next Annual Enrollment Period.

Does Medicare cover Mounjaro or Zepbound? Medicare Part D covers Mounjaro (tirzepatide) when prescribed for type 2 diabetes. Zepbound (tirzepatide for obesity) is excluded under the weight loss medication rule. The coverage pattern is identical to Ozempic and Wegovy.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. CMS.gov. 2026.
2. Johnson AL, et al. Prior Authorization Approval Rates for GLP-1 Receptor Agonists in Medicare Part D. JAMA Health Forum. 2025;6(3):e254432.
3. Social Security Administration. Extra Help with Medicare Prescription Drug Plan Costs. SSA.gov. 2025.
4. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173. Section 1860D-2(e)(2)(A).
5. Kaiser Family Foundation. Medicare Part D Spotlight: Formulary Placement and Cost-Sharing for Specialty Drugs. KFF.org. 2026.
6. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2022. CDC.gov. 2022.
7. American Medical Association. AMA Adopts New Policy Recognizing Obesity as a Disease. AMA-assn.org. June 2013.
8. Code of Federal Regulations. 42 CFR § 423.100. Definitions.
9. U.S. Code. 42 U.S.C. § 1320a-7b(b). Criminal Penalties for Acts Involving Federal Health Care Programs (Anti-Kickback Statute).
10. Novo Nordisk. Ozempic Prescribing Information. NovoMedLink.com. Revised 2024.
11. Eli Lilly. Mounjaro Prescribing Information. Lilly.com. Revised 2024.
12. Centers for Medicare & Medicaid Services. Medicare Plan Finder Formulary Data. Medicare.gov. Accessed April 2026.
13. GoodRx Research. Medicare Part D Coverage and Prior Authorization Requirements for GLP-1 Medications. GoodRx.com. 2025.
14. Wilkinson L, et al. Obesity Prevalence Among Adults with Type 2 Diabetes in the United States. Diabetes Care. 2023;46(4):892-899.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare is a registered trademark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.